Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 22 SHARE-BASED PAYMENTS (CONTINUED) The expense for the 2026 financial year includes the impact of the reversal of previously recognised expense on unvested options that were cancelled after the departure of former IIQ Chairman, David Williams. During the 2025 financial year, the Company issued 1,000,000 options under INOVIQ’s Incentive Option Plan to NonExecutive Directors and a further 150,000 options were also issued to employees. 23 AUDITOR’S REMUNERATION For the year ended 30 June 2026 $ For the year ended 30 June 2025 $ Amounts received or due and receivable by the Company’s auditors Grant Thornton Pty Ltd for: - Auditing or review of the financial statements. 128,625 123,375 128,625 123,375 24 RELATED PARTY DISCLOSURES Other related party transactions (A) WHOLLY OWNED GROUP TRANSACTIONS Details of interests in controlled entities are set out in Note 25. (B) ULTIMATE PARENT COMPANY INOVIQ Limited is the ultimate legal Australian holding Company. (C) TRANSACTIONS WITH OTHER RELATED PARTIES The Company did not have other transactions with related parties in the 2026 financial year. In the 2025 financial year Kidder Williams, a Corporate Advisory and Investment Banking services firm owned by former INOVIQ Chairman David Williams, received Corporate Advisory fees from INOVIQ during the year totalling $10,000. Kidder Williams also advised INOVIQ on its 2024 capital raise, receiving $65,080 for services provided in conjunction with the SPP and director placement component of the raising. 25 CONTROLLED ENTITIES Consolidated entities of INOVIQ Ltd Country of Incorporation Equity Interest held % 30 June 2026 30 June 2025 Sienna Cancer Diagnostics Limited Australia 100 100 INOVIQ Inc. (formerly Sienna Cancer Diagnostics Inc.) U.S.A. 100 100 Melbourne Diagnostics Pty Ltd Australia 100 100 26 EVENTS SUBSEQUENT TO BALANCE DATE On 1 July 2026, IIQ announced an enhanced EXO-OC™ algorithm and that samples from its retrospective clinical study were unsuitable for evaluating the test. Data analysis completed in June 2026, identified that samples from a biorepository, which supplied most samples (616 including 69% of the cancer cases), exhibited reduced protein and miRNA levels consistent with sample degradation, rendering these samples unsuitable for inclusion in the study. Additionally, significant variability was identified across all biorepositories, likely due to provider-specific pre-analytical collection and logistical factors, outside the control of the study. Importantly, these issues were unrelated to the performance of the EXO-NET® technology or EXO-OC™ test. As a result of these issues, the 1200 samples were deemed unsuitable for evaluation of the EXO-OC™ ovarian cancer test. Notwithstanding, the inferior sample quality, the study generated valuable insights into the robustness and performance of individual miRNA biomarkers under uncontrolled pre-analytical conditions, which will inform future development plans, study design and commercial roll-out. 57 Annual Report 2026
RkJQdWJsaXNoZXIy MjE2NDg3